Oncotarget cover image

Novel Triple-Drug Combination to Fight Pancreatic Cancer

Oncotarget

00:00

Synergistic Drug Strategy Against Pancreatic Cancer

This chapter explores a novel approach to pancreatic cancer treatment involving a triple-drug combination that includes histone deacetylase inhibitors, PARP inhibitors, and decitabine. It highlights their synergistic effects on inducing apoptosis and interrupting DNA repair mechanisms, offering hope for enhanced patient outcomes.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app